DELLA PORTA, MATTEO GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 2.909
EU - Europa 2.104
AS - Asia 1.464
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 8
SA - Sud America 2
Totale 6.507
Nazione #
US - Stati Uniti d'America 2.876
CN - Cina 1.435
IE - Irlanda 616
UA - Ucraina 405
FI - Finlandia 356
DE - Germania 213
IT - Italia 166
SE - Svezia 158
GB - Regno Unito 97
FR - Francia 42
CA - Canada 31
BE - Belgio 14
RU - Federazione Russa 11
EU - Europa 10
NL - Olanda 10
JP - Giappone 9
AU - Australia 8
MU - Mauritius 8
IN - India 5
RO - Romania 5
TR - Turchia 5
CZ - Repubblica Ceca 3
SA - Arabia Saudita 3
AT - Austria 2
BR - Brasile 2
HK - Hong Kong 2
BD - Bangladesh 1
CH - Svizzera 1
DK - Danimarca 1
EG - Egitto 1
GR - Grecia 1
ID - Indonesia 1
IL - Israele 1
IQ - Iraq 1
MD - Moldavia 1
MX - Messico 1
PA - Panama 1
PL - Polonia 1
PT - Portogallo 1
SG - Singapore 1
ZA - Sudafrica 1
Totale 6.507
Città #
Chandler 708
Dublin 616
Jacksonville 522
Nanjing 459
Ashburn 206
Nanchang 176
Princeton 140
Lawrence 134
Wilmington 129
Changsha 125
Hebei 116
Medford 110
Shenyang 106
Helsinki 100
Jiaxing 92
Boardman 88
Beijing 79
Tianjin 72
Ann Arbor 68
Hangzhou 67
New York 56
Pavia 44
Milan 43
Shanghai 35
Woodbridge 30
Toronto 27
Norwalk 25
Falls Church 16
Verona 16
Washington 15
Brussels 14
Seattle 14
Des Moines 11
Los Angeles 11
Dearborn 10
Fairfield 10
Kunming 10
San Francisco 9
Taizhou 9
Zhengzhou 9
Jinan 8
Ningbo 8
Tokyo 8
Guangzhou 6
Houston 6
Fuzhou 5
Tappahannock 5
Auburn Hills 4
Orange 4
Canberra 3
Chicago 3
Falkenstein 3
Haikou 3
Kemerovo 3
Lanzhou 3
Leawood 3
Munich 3
Taranto 3
Amsterdam 2
Borås 2
Brno 2
Catania 2
Changchun 2
Gießen 2
Melbourne 2
Paris 2
Qingdao 2
Redwood City 2
Wuhan 2
Agra 1
Andover 1
Berlin 1
Bolgare 1
Buffalo 1
Cairo 1
Central 1
Centurion 1
Changzhou 1
Chisinau 1
Desenzano Del Garda 1
Dhaka 1
Easton 1
Edmonton 1
Foshan 1
Ganzhou 1
Groningen 1
Grumo Appula 1
Gustavo Adolfo Madero 1
Haifa 1
Hefei 1
Hengyang 1
Hong Kong 1
London 1
Monmouth Junction 1
Monsummano Terme 1
Montreal 1
Novokuznetsk 1
Osaka 1
Phoenix 1
Pune 1
Totale 4.661
Nome #
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 81
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 80
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 79
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 77
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 76
Prognosis of secondary acute myeloid leukemia 76
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 72
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 71
Over-expression of mitochondrial ferritin affects the JAK2/STAT5 pathway in K562 cells and causes mitochondrial iron accumulation. 70
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 69
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. 69
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 69
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 67
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 67
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 67
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 67
Classification and prognostic evaluation of myelodysplastic syndromes 67
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 67
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 67
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 65
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 65
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia 65
Dendritic cells in acute promyelocytic leukaemia. 64
Myelodysplastic syndromes and bone marrow microenvironment. 64
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 63
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 63
CD34 and CD2 expression in acute promyelocytic leukemia. 63
Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. 63
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 62
In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. 61
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes 60
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 60
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 60
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 59
Clinical and biological implications of driver mutations in myelodysplastic syndromes 59
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 59
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 58
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 58
Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome 58
Ultrastructural and functional differences between normal and tumor endothelial progenitor cells 58
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 57
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 57
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 57
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 56
Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. 56
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 56
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 56
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome 56
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 56
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 55
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 55
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 55
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 55
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 55
Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. 54
Improving the prognostic assessment of myelodysplastic syndromes by understanding the biology of the disease 54
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 54
From cancer patients to cancer survivors: the issue of Cardioncology--a biological perspective. 54
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 53
Simian virus 40 and lymphoproliferative disorder. 53
Role of the molecular staging and response in the management of follicular lymphoma patients 53
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. 53
Risk factors for Gram-negative infections in neutropenic patients. 53
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 53
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 52
rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. 52
Splenectomy for treatment of immune thrombocytopenic purpura. 51
Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. 51
High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene. 51
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. 51
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 51
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 51
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study 50
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 49
Prevalence, incidence and types of mild anemia in the elderly: the "Health and Anemia" population-based study. 48
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome 48
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 48
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome 47
Myelodysplastic syndromes with bone marrow fibrosis. 47
Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. 47
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. 47
The genetic basis of myelodysplasia and its clinical relevance 47
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia 47
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 46
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. 45
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 44
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 44
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype 44
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 43
Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes. 43
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 43
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 42
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. 42
Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need 42
The Effects of Mitochondrial Ferritin Expression in Normal and Sideroblastic Erythropoiesis 42
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 42
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. 42
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 42
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens. 41
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. 41
Totale 5.624
Categoria #
all - tutte 24.436
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.436


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.677 525 726 2 71 3 81 14 83 3 124 39 6
2020/2021705 84 64 20 76 7 93 9 117 19 108 91 17
2021/2022661 9 0 21 12 36 20 10 31 39 29 86 368
2022/20231.859 182 105 20 197 204 198 2 129 748 13 37 24
2023/2024706 58 185 30 66 56 190 11 27 3 16 29 35
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 6.700